Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
The Motley Fool7d
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
It notched a convincing beat on net income. The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as ...
Yahoo26d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...
Hosted on MSN1mon
Regeneron expands eye care focus with Oxular buyout
Regeneron Pharmaceuticals (NASDAQ:REGN), the maker of eye disease therapy Eylea, has acquired Oxular, a U.K.-based biotech drug developer focused on ophthalmology. While neither company formally ...
Morningstar7d
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Anti-inflammatory Dupixent's sales are up 15%, and a midstage trial of treatment for muscle loss caused by obesity drugs is fully enrolled Regeneron Pharmaceuticals Inc.'s stock rose 4.9% Tuesday ...
Yahoo Finance29d
Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database
DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...
Yahoo Finance26d
UBS cuts rating on Regeneron stock amid Eylea uncertainty
Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ ... shorter-term focus on Eylea revenues vs. REGN's focus on building a long-term sustainable business,” analyst said.
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
Reuters29d
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...
FiercePharma28d
JPM25: Regeneron CEO says it needs more 'arrows in its quiver' as Eylea HD sales fall short
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...
U.S. News & World Report7d
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program
(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...